Purdue Pharma L.p.

Accencio LLC

Shionogi Company Limited

Purde Pharma L.p.

Accencio Lc

Kevin Brown

Kevin Brogle

Paul Blake

Don Kyle

R Richard Goehring

Naoki Tsuno

John W F Whitehead

Timothy John Doyle

Xiaoming Zhou

Nobuyuki Tanaka

Dawit Tadesse

Yoshiyasu Baba

The present disclosure relates to a method of reducing or arresting viral load in a subject infected with a coronavirus, the method comprising the step of administering to the subject a therapeutically effective amount of a viral protease inhibitor. In some embodiments, the subject is a human. In one embodiment, the coronavirus is SARS-CoV-19 and the viral protease inhibitor is frovatriptan (6R)-6-(methylamino)-6,7,8,9-tetrahydro-5H-carbazole-3-carboxamide.

Methods of treating symptoms of coronavirus infection with viral protease inhibitors

A method of treating or alleviating at least one symptom of a coronavirus infection in a subject, by administering to the subject a therapeutically effective amount of an RNA polymerase inhibitor. In some embodiments, the symptom is selected from the group consisting of fever, cough, tiredness, sore throat, diarrhea, conjunctivitis, headache, loss of taste, loss of smell, rash, difficulty breathing, shortness of breath, chest pain, chest pressure, Acute Respiratory Distress Syndrome (ARDS) and organ failure.

Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors

The present invention is directed to generating structured text document from the output of a query for compounds using a n-dimensional map where the n-dimensional map includes an arrangement of biological or chemical entities enumerated within a collection of documents describing a particular biological target of interest.

System and method for evaluating data using and applying a virtual landscape

The present disclosure relates to a method of reducing or arresting viral load in a subject infected with a coronavirus, the method comprising the step of administering to the subject a therapeutically effective amount of a viral protease inhibitor. In some embodiments, the subject is a human. In one embodiment, the coronavirus is SARS-COV-19 and the viral protease inhibitor is E)-N-(4-(3-(tert-butyl)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxystyryl)phenyl)methanesulfonamide; (R)-3-((2S,3S)-2-hydroxy-3-(3-hydroxy-2-methylbenzamido)-4-phenylbutanoyl)-5,5-dimethyl-N-(2-methylbenzyl)thiazolidine-4-carboxamide; R)—N-allyl-3-((2S,3S)-2-hydroxy-3-(3-hydroxy-2-methylbenzamido)-4-phenylbutanoyl)-5,5-dimethylthiazolidine-4-carboxamide; (4-((N-(5-cyclopropyl-2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-6-yl)methylsulfonamido)methyl)-2-fluorophenyl)boronic acid or salts thereof.

The present invention is directed to generating an n-dimensional map using the results of a query for compounds enumerated within a collection of documents describing a particular biological target of interest and a curated set of compounds not enumerated in the collection of documents. Both sets of compounds (document coded and curated coded) are converted into coded forms and placed in the n-dimensional map. One or more processors are configured to evaluate the distance between the curated coded forms and the closest cluster of document coded forms. Based on the distance between a coded form and the document coded forms, the curated coded forms can be ranked regarding the likelihood of interacting with the particular biological target.

System and method for evaluating chemical compound data using and applying a virtual landscape

A system and method for extrapolating a set of specific representational identifiers that are represented or covered by a generic representational identifier found in a target document. Queries are constructed and performed on a corpus of source documents in which members of the extrapolated set of specific representational identifiers are compared to a database of representational data. By matching representational data in this way, any overlap between the generic representational data and specific instances of the generic representational identifier within the source documents is determined. In a more specific implementation, the system and method reduces the scope of the generic representational identifier such that the reduced scope generic representational identifier encompasses only novel specific representational identifiers.

Chemical formula extrapolation and query building to identify source documents referencing relevant chemical formula moieties

The disclosure relates to Substituted Piperidin-4-amino-Type Compounds of Formula (I) and pharmaceutically acceptable salts and solvates thereof wherein R, R, R, Q, Q, E, E, A, B, D, W, Z, a, b, n, and x are as defined herein, compositions comprising an effective amount of a Substituted Piperidin-4-amino-Type Compound, and methods to treat or prevent a condition, such as pain, comprising administering to an animal in need thereof an effective amount of a Substituted Piperidin-4-amino-Type Compound. 

Substituted piperidin-4-amino-type compounds and uses thereof

The invention relates to Heterocyclic-Substituted Piperidine Compounds, compositions comprising an effective amount of a Heterocyclic-Substituted Piperidine Compound and methods to treat or prevent a condition, such as pain, comprising administering to an animal in need thereof an effective amount of a Heterocyclic-Substituted Piperidine Compound.

2,3,4,5-tetrahydro-benzo{B}{1,4}diazepine-comprising compounds of formula(III) for treating pain

Compounds comprising heterocyclic-substituted piperidine for treating pain

Methods, composition, and intermediates are disclosed that are useful for making 4-Tetrazolyl-4-phenylpiperidine Compounds according to Formula I, where Aris &#x2014;C-Ccycloalkyl, phenyl, naphthyl, anthryl, phenanthryl or -(5-7-membered) heteroaryl, each being unsubstituted or substituted with one or more Rgroups; Aris phenyl, naphthyl, anthryl, phenanthryl or -(5-7-membered) heteroaryl, each being unsubstituted or substituted with one or more Rgroups; Zand Zare each independently a &#x2014;(C-Calkyl) group; Ris &#x2014;(CH)C(O)N(R)(R) where Rand Rare each independently H or &#x2014;(C-Calkyl); Ris halogen, &#x2014;C-Calkyl, &#x2014;O&#x2014;(C-Calkyl), &#x2014;NH(C-Calkyl) or &#x2014;N(C-Calkyl); n is an integer ranging from 1 to 4; m is an integer ranging from 0 to 4; and, in certain embodiments, the phenyl moiety attached to the 4-position of the piperidine ring of a compound according to Formula I can be optionally substituted with one or more Rgroups.

Growing community of inventors

Philadelphia, PA, United States of America

Kevin Brown